Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
68.00    0.60 (0.89%)
Bid:
67.80
Ask:
67.90
Spread: 0.10 (0.147%)
Market Cap: £600.73m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

DBSP awards; Director/PDMR shareholding

25 Apr 2022 18:09

RNS Number : 2734J
IP Group PLC
25 April 2022
Β 

FOR RELEASE ON

25 APRIL 2022

Β 

IP Group plc - DBSP awards; Director/PDMR shareholding

Β 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), whichΒ develops world-changing science and technology businesses across life sciences, technology and cleantech, announces the following in connection with its employee share schemes.

Β 

Deferred Bonus Share Plan ("DBSP") Awards

Β 

IP Group has granted nil-cost options over ordinary shares of two pence each ("Shares") to the executive directors and persons discharging managerial responsibilities ("PDMRs") under the Group's DBSP on 21 April 2022. The grants reflect the deferral of fifty per cent of each person's award above Β£25,000 under the Group's Annual Incentive Scheme ("AIS") in respect of the Group's performance for the financial year ended 31 December 2021. The following table sets out details of the awards made to the Executive Directors and PDMRs:Β 

Β 

Name of Director/PDMR

Structure of award

Number of options granted

Total number of options currently held

Greg Smith

Nil-Cost Option

176,200

298,403

David Baynes

Nil-Cost Option

150,902

269,013

Sam Williams

Nil-Cost Option

82,364

153,086

Mark Reilly

Nil-Cost Option

94,736

160,210

Angela Leach

Nil-Cost Option

58,224

102,758

Christopher Glasson

Nil-Cost Option

41,088

64,980

Lisa Patel

Nil-Cost Option

3,680

5,970

Liz Vaughan-Adams

Nil-Cost Option

38,272

52,664

Moray Wright

Nil-Cost Option

84,876

88,260

Dan Xie

Nil-Cost Option

29,790

44,874

Anthony York

Nil-Cost Option

33,498

33,498

Total

Β 

793,630

1,273,716

Β 

In addition to the above, awards over a total of 1,272,544 Shares were made to certain other of the Group's employees. As at the date of this announcement, a total of 3,377,871 nil-cost options over Shares remain outstanding under the IP Group DBSP.

Β 

No consideration was paid for the grant of the awards and no consideration is due on the maturity of the option period. Fifty per cent of the options will normally be automatically exercised on 31 March 2023 and fifty per cent on 31 March 2024, with each such automatic exercise generally subject to continued employment.

Shares in issue

At the date of this announcement, the Company continues to have 1,063,033,287 Shares in issue and 28,938,473 Shares held in treasury.

Β 

The following information is being disclosed pursuant to the requirements of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Β 

DBSP awards

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Greg SmithDavid BaynesSam WilliamsMark ReillyAngela LeachChristopher Glasson

Lisa Patel

Liz Vaughan-Adams

Moray Wright

Dan Xie

Anthony York

2

Reason for the notification

a)

Position/status

Director Chief Executive OfficerDirector Chief Operating and Financial OfficerPDMR Managing Partner, Life SciencesPDMR Managing Partner, TechnologyPDMR General Counsel & Company Secretary

PDMR Finance Director

PDMR Partner, Employee Executive

PDMR Director of Communications

PDMR CEO Parkwalk

PDMR Partner, Employee Executive

PDMR Group People Director

Β 

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IP Group plc

b)

Legal Entity Identifier

213800HG22UM138WFG43

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary Shares of 2p each in IP Group plc

Β 

Β ISIN: GB00B128J450

b)

Nature of the transaction

Grant of nil-cost options under the IP Group plc DBSP

c)

Currency

GBP

d)

Price(s) and volume(s)

Name(s)

Price(s)

Volume(s)

Greg Smith

Nil cost option

176,200

David Baynes

Nil cost option

150,902

Sam Williams

Nil cost option

82,364

Mark Reilly

Nil cost option

94,736

Angela Leach

Nil cost option

58,224

Christopher Glasson

Nil cost option

41,088

Lisa Patel

Nil cost option

3,680

Liz Vaughan-Adams

Nil cost option

38,272

Moray Wright

Nil cost option

84,876

Dan Xie

Nil cost option

29,790

Anthony York

Nil cost option

33,498

Β 

e)

Aggregated information

-Aggregated volume

- Price

- Aggregated total

Β 

Aggregated number of options granted under the DBSP to Directors and PDMRs on 21 April 2022: 793,630

Price: Β£ nil

f)

Date of the transaction

21 April 2022

g)

Place of the transaction

Outside a trading venue

Β 

Β 

Β 

For more information, please contact:

Β 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Β 

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

Β 

Notes for editors

Β 

About IP Group

Β 

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Β 

For more information, please visit our website at www.ipgroupplc.com.

Β 

ENDS

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHUVRBRUWUSUAR
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.